Management of fluoroquinolone resistance in Pseudomonas aeruginosa - Outcome of monitored use in a referral hospital

International Journal of Antimicrobial Agents

Volumn 10, Issue 3, 1998, Pages 207-214

  Peterson, L R ^a   Postelnick, M ^b   Pozdol, T L ^b   Reisberg, B ^a   Noskin, G A ^a  

^a NW Mem H   (United States)

^b Clinical Microbiology Laboratory   (United States)

Author keywords

Antimicrobial drug resistance; Fluoroquinolone; Formulary management; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; OFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG FORMULARY; DRUG USE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DISEASE MANAGEMENT; DRUG MONITORING; DRUG RESISTANCE, MICROBIAL; EVALUATION STUDIES; HOSPITALS, TEACHING; HUMANS; OFLOXACIN; PSEUDOMONAS INFECTIONS; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 0032143537     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00045-4     Document Type: Article

References (27)

1. Eilopoulos GM, Eilopoulos CT. Activity in vitro of the quinolones. Hooper DC, Wolfson JS Quinolone Antimicrobial Agents. American Society for Microbiology. 8:1993;161-193 American Society for Microbiology, Washington, DC.
2. Kunin CM Resistance to antimicrobial drugs - a worldwide calamity. Ann Int Med. 118:1993;557-561.
3. Armstrong D, Neu H, Peterson LR, Tomasz A. The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990s. Microb Drug Resist. 1:1995;1-4.
4. Mouton RP, Glerum JH, vanLoenen AC. Relationship between antibiotic consumption and frequency of antibiotic resistance of four pathogens - a 7-year survey. J Antimicrob Chemother. 2:1976;9-19.
5. Ma MY, Goldstein EJC, Friedman MH, Anderson MS, Mulligan ME. Resistance of gram-negative bacilli as related to hospital use of antimicrobial agents. Antimicrob Agents Chemother. 24:1983;347-352.
6. McGowan JE. Jr Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis. 5:1983;1033-1048.
7. Moller JK. Antimicrobial usage and microbial resistance in a university hospital during a 7-year period. J Antimicrob Chemother. 24:1989;983-992.
8. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer CJ, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: 10 years of experience in one hospital. Antimicrob Agents Chemother. 35:1991;1284-1290.
9. Muder RR, Brenner C, Goez AM, Wagener MM, Rihs JD Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a veterans affairs medical center. Antimicrob Agents Chemother. 35:1991;256-258.
10. Peterson, LR. Quinolone resistance in clinical practice: occurrence and importance. In: Hooper DC, Wolfson JS (Eds.). Washington DC: American Society for Microbiology, 1993:6;119-37.
11. Richard P, Delangle MH, Merrien D, Barille S, Reynaud A, Minozzi C, Richet H. Fluoroquinolone usage and fluoroquinolone resistance: is there an association? Clin Infect Dis. 19:1994;54-59.
12. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. New Engl J Med. 330:1994;1240-1241.
13. Carratalá J, Fernandaz-Sevilla A, Tuber F, Callis M, Gudiol F. Emergence of quinoloneresistant Escherichia coli bacteremia in neutropenic patients. Clin Infect Dis. 20:1995;560-577.
14. Felrningham D, Foxall P, O'Hare MD, Webb G, Ghosh G, Gruneberg RN. Resistance studies with ofloxacin. J Antimicrob Chemother. 22 (Suppl C):1988;27-34.
15. Neu HC. The crisis in antibiotic resistance. Science. 257:1992;1064-1073.
16. Brown SD, Washington JA II Evaluation of the Repliscan system for identification of the Enterobacteriaceae. J Clin Microbiol. 8:1978;695-699.
17. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-fourth edition; Approved Standard. NCCLS Document M7-A4-1997. Villanova, PA.
18. Winquist A, Ristow T, Posteloick M, Oliphant C, Engman D, Peterson L. Fluoroquinoloneresistant Pseudomonas aeruginosa is not related to spread of a drug-resistant clone. Abstract of the 95th Annual Meeting of the American Society for Microbiology, May 21-25, 1995, Washington, DC. Abstract #A104.
19. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P, and the Finnish Study Group for Antimicrobial Resistance The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. New Engl J Med. 337:1997;441-446.
20. Tumidge J. Epidemiology of quinolone resistance: Eastern hemisphere. Drugs. 49 (Suppl 2):1995;43-47.
21. Elhanan G, Raz R. Oral fluoroquinolone use in the community. Isr J Med Sci. 31:1995;59-61.
22. Oliphant CM, Postelaick M, Noskin GA, Peterson LR. The impact of use reduction on the antipseudomonal activity of fluoroquinolones. Abstract of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco, CA. Abstract #C52.
23. Kunin CM. Use of antimicrobial drugs in developing countries. Int J Antimicrob Agents. 5:1995;107-113.
24. Editor. New antimicrobial agents approved by the US Food and Drug Administration in 1994 and new indications for previously approved agents. Antimicrob Agents Chemother 1995; 39:1010.
25. Editor. New antimicrobial agents approved by the US Food and Drug Administration in 1995 and new indications for previously approved agents. Antimicrob Agents Chemother 1996; 40:1063.
26. Lorber B. Changing pattems of infectious diseases. Am J Med. 84:1988;569-578.
27. Lorber B. Are all diseases infectious? Ann Int Med. 125:1996;844-851.